Sua Taliah, Montoya Carlos, Luo Dongwen, Rostami Kamran
University of Otago, Wellington, New Zealand.
AgResearch, Massey University, Palmerston North, New Zealand.
Gastroenterol Hepatol Bed Bench. 2023;16(2):210-216. doi: 10.22037/ghfbb.v16i2.2761.
This study aimed at assessing the efficacy of targeted interventions addressing common food sensitivities and lifestyle factors that commonly contribute to the presentation of gastrointestinal problems identified as Irritable bowel syndrome (IBS).
IBS has served to cover the expression of multifactorial disorders with variable aetiology and pathophysiology. Food antigens implicated in the modern lifestyle, acting as strong epigenetic factors is strongly implicated in pathophysiology of conditions under IBS. Identifying and addressing food sensitivities in patients presenting with IBS like symptoms are currently underemphasised in clinical guidelines yet have the potential to provide major benefits for patients.
Information was collected from the medical records of patients that were referred to the Gastroenterology Unit of Palmerston North DHB with unexplained gastrointestinal (GI) symptoms with or without other GI comorbidities between September 2018 and November 2021.
The main management option offered to the 121 patients included in this study, was lifestyle adjustment and/or a trial of 6 weeks, eliminating gluten and lactose from the diet. The most prevalent symptoms were abdominal pain 96/121 (79%), diarrhoea 83/121 (69%), followed by bloating and constipation. Seventy-eight patients had the outcomes of their improvement available. A total of 42 out of 78 patients (54%) were treated exclusively with gluten and lactose-free diet, in this group of patients 86% (36/42) reported a significant improvement in their symptoms with a score in the range of 40-100%.
Our study illustrates the importance of focusing on triggering factors when assessing patients with IBS. We suggest that careful identifying and eliminating the triggering food antigens as monotherapy or in addition to the lifestyle adjustment where appropriate should be the main objective in symptomatic patients fulfilling the IBS diagnostic criteria. These combinations and holistic approach in treating IBS' patients' symptoms are less expensive, non-toxic, and highly effective in achieving optimal outcomes and improving these patient's quality of life.
本研究旨在评估针对常见食物敏感性和生活方式因素的靶向干预措施的疗效,这些因素通常会导致被诊断为肠易激综合征(IBS)的胃肠道问题。
IBS涵盖了病因和病理生理多变的多因素疾病。现代生活方式中涉及的食物抗原作为强大的表观遗传因素,与IBS相关疾病的病理生理密切相关。目前临床指南对出现IBS样症状的患者识别和处理食物敏感性重视不足,但这有可能为患者带来重大益处。
收集了2018年9月至2021年11月期间转诊至北帕默斯顿地区卫生局胃肠病科、有或无其他胃肠道合并症的不明原因胃肠道(GI)症状患者的病历信息。
本研究纳入的121名患者的主要管理选项包括生活方式调整和/或为期6周的试验,即从饮食中去除麸质和乳糖。最常见的症状是腹痛96/121(79%)、腹泻83/121(69%),其次是腹胀和便秘。78名患者有改善结果。78名患者中共有42名(54%)仅接受了无麸质和无乳糖饮食治疗,在这组患者中,86%(36/42)报告症状有显著改善,评分在40 - 100%范围内。
我们的研究说明了在评估IBS患者时关注触发因素的重要性。我们建议,对于符合IBS诊断标准的有症状患者,仔细识别并消除触发食物抗原作为单一疗法,或在适当情况下结合生活方式调整,应是主要目标。这些综合和整体的方法在治疗IBS患者症状方面成本更低、无毒,并且在实现最佳结果和改善这些患者的生活质量方面非常有效。